Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

If you're interested in exploring more stocks under $10 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Investing in stocks under $10 could ...

While we looked at eligibility requirements and premium rates, we also looked at policies on conversions as well as companies that cover specific groups of people, such as military personnel and ...